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Gene-activated matrix (GAM)-based therapeutics for tissue re- generation are limited by efficacy, 
the lack of spatiotemporal control and availability of target cells, all of which impact negatively 
on their translation to the clinic. Here we describe an advanced ultrasound-responsive GAM 
containing target cells that facilitates matrix-assisted sonoporation (MAS) to induce osteogenic 
differentiation. Ultrasound-responsive GAMs consisting of fibrin/collagen hybrid-matrices 
containing microbubbles, bone morphogenetic protein BMP2/7 co-expression plasmids together 
with C2C12 cells were treated with ultrasound either in vitro or following parenteral intramuscular 
implantation in vivo. Using direct measurement for alkaline phosphatase activity, von Kossa 
staining and immuno- histochemical analysis for osteocalcin expression, MAS-stimulated 
osteogenic differentiation was confirmed in the GAMs in vitro 7 days post treatment with 
ultrasound. At day 30 post-treatment with ultrasound, ectopic osteogenic differentiation was 
confirmed in vivo using X-ray microcomputed tomography (µCT) and histological analysis. 
Osteogenic differentiation was indicated by the presence of ectopic bone structures in all animals 
treated with MAS when compared with controls. In addition, bone volumes in this group were 
statistically greater than those in the control groups. This novel approach of incorporating a MAS 
capability into GAMs could provide a minimally invasive means of stimulating in situ transgene 
delivery with enhanced spatiotemporal control for osteoinductive gene-based therapies.  
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